Q-omics provides the consensus-scored SIX1 profile across patient tissues and cancer cell-line models. SIX1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SIX1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, SIX1 protein abundance shows 29,341 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, BLCA, and LUAD as cancer lineages where SIX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIX1 survival associations across molecular data types. SIX1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIX1 RNA expression–survival associations across cancer types. High SIX1 expression shows unfavorable associations in KIRP, UCEC, ACC and UVM, but favorable associations in LUSC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SIX1 RNA expression.
This table summarizes SIX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SIX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIX1 shows higher tumor expression in BLCA, KIRC, KIRP, LUAD, LIHC and COAD. The BLCA box plot shows higher SIX1 RNA expression in tumor versus normal tissue (log2 FC = +1.811, t-test p < 0.001).
This table shows molecular features associated with SIX1 in patient tissues and cancer cell lines. In patient samples, SIX1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SIX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
